[{"notes_id":"1_175","category":"4","subcategory":"1","title":"<i>Clostridioides difficile<\/i>","body":"<i>Clostridioides difficile<\/i> is a <span class=\"concept\" data-cid=\"1867\">Gram positive rod<\/span> often encountered in hospital practice. It produces an exotoxin which causes intestinal damage leading to a syndrome called pseudomembranous colitis. <i>C. difficile<\/i> develops when the normal gut flora are suppressed by broad-spectrum antibiotics. <span class=\"concept\" data-cid=\"987\">Clindamycin<\/span> is historically associated with causing <i>C. difficile<\/i> but the aetiology has evolved significantly over the past 10 years. Second and third-generation <span class=\"concept\" data-cid=\"431\">cephalosporins<\/span> are now the leading cause of <i>C. difficile<\/i>.<br \/><br \/>Other than antibiotics, risk factors include:<br \/><ul><li><span class=\"concept\" data-cid=\"1773\">proton pump inhibitors<\/span><\/li><\/ul><br \/>Pathophysiology<br \/><ul><li>anaerobic gram-positive, spore-forming, toxin-producing bacillus <\/li><li>transmission: via the <span class=\"concept\" data-cid=\"12028\">faecal-oral route by ingestion of spores<\/span><\/li><li>releases two exotoxins (toxin A and toxin B) that act on intestinal epithelial cells and inflammatory cells resulting in colitis<\/li><\/ul><br \/>Features<br \/><ul><li>diarrhoea<\/li><li>abdominal pain<\/li><li>a <b>raised white blood cell count (WCC)<\/b> is characteristic<\/li><li>if severe toxic megacolon may develop<\/li><\/ul><br \/>The Public Health England severity scale is often used as this may determine treatment:<br \/><br \/><div class=\"table-responsive\"><table class = \"tlarge table table-striped table-bordered\"  data-role=\"table\" id=\"tableid1\" ><thead><tr><th>Mild<\/th><th>Moderate<\/th><th>Severe<\/th><th>Life-threatening<\/th><\/tr><\/thead><tbody><tr><td><span class=\"concept\" data-cid=\"11061\">Normal WCC<\/span><\/td><td><span class=\"concept\" data-cid=\"11061\">\u2191 WCC ( < 15 x 10<sup>9<\/sup>\/L)<\/span><br \/>Typically 3-5 loose stools per day<\/td><td><span class=\"concept\" data-cid=\"11061\">\u2191 WCC ( > 15 x 10<sup>9<\/sup>\/L)<\/span><br \/>  or an acutely \u2191 creatinine (> 50% above baseline)<br \/>  or a temperature > 38.5\u00b0C<br \/> or evidence of severe colitis(abdominal or radiological signs)<\/td><td>Hypotension<br \/>Partial or complete ileus<br \/>Toxic megacolon, or CT evidence of severe disease<\/td><\/tr><\/tbody><\/table><\/div><br \/>Diagnosis<br \/><ul><li>is made by detecting <i>C. difficile<\/i> <b>toxin<\/b> (CDT) in the stool<\/li><li><i>C. difficile<\/i> <span class=\"concept\" data-cid=\"9585\"><b>antigen<\/b> positivity only shows exposure to the bacteria, rather than current infection<\/span><\/li><\/ul><br \/><h5 class='notes-heading'>Management<\/h5><br \/>Current antibiotic therapy should be reviewed and antibiotics stopped if possible.<br \/><br \/>First episode of <i>C. difficile<\/i> infection<br \/><ul><li><b>first-line therapy is <span class=\"concept\" data-cid=\"1524\">oral vancomycin<\/span><\/b> for 10 days<\/li><li>second-line therapy: <span class=\"concept\" data-cid=\"4516\">oral fidaxomicin<\/span> <\/li><li>third-line therapy: <span class=\"concept\" data-cid=\"11463\">oral vancomycin +\/- IV metronidazole<\/span><\/li><\/ul><br \/>Recurrent episode <br \/><ul><li>recurrent infection occurs in around 20% of patients, increasing to 50% after their second episode<\/li><li><span class=\"concept\" data-cid=\"11464\">within 12 weeks of symptom resolution: oral fidaxomicin<\/span><\/li><li>after 12 weeks of symptom resolution: oral vancomycin OR fidaxomicin<\/li><\/ul><br \/>Life-threatening <i>C. difficile<\/i> infection<br \/><ul><li><span class=\"concept\" data-cid=\"1489\">oral vancomycin AND IV metronidazole<\/span><\/li><li>specialist advice - surgery may be considered<\/li><\/ul><br \/>Other therapies<br \/><ul><li><span class=\"concept\" data-cid=\"2406\">bezlotoxumab<\/span> is a monoclonal antibody which targets <i>C. difficile<\/i> toxin B<ul><li>NICE do not currently support its use to prevent recurrences as it is not cost-effective<\/li><\/ul><\/li><li>faecal microbiota transplant<ul><li>may be considered for patients who've had 2 or more previous episodes<\/li><\/ul><\/li><\/ul><br \/><span class=\"concept\" data-cid=\"12138\">Preventing the spread of <i>C. difficile<\/i> infection<\/span><br \/><ul><li><span class=\"concept\" data-cid=\"3075\">isolation in side room<\/span>: the patient should remain isolated until there has been no diarrhoea (types 5-7<\/li><\/ul>on the Bristol Stool Chart) for at least 48 hours<br \/><ul><li>all staff should wear disposable gloves and an apron during any contact with patients known to have <i>C. difficile<\/i><\/li><li>hand washing is also essential - alcohol gel does not kill the spores of <i>C. difficile<\/i><\/li><\/ul><br \/><div class=\"container\"><div class=\"row\"><div class=\"col-md-3\"><a href=\"https:\/\/d32xxyeh8kfs8k.cloudfront.net\/images_Passmedicine\/xrb133b.jpg\" data-fancybox=\"gallery\" data-caption=\"Elderly lady with infectious colitis secondary to <i>C. difficile<\/i>. On the abdominal film note the loss of bowel wall architecture and thumb-printing consistent with colitis. The CT from the same patient is enhanced by oral contrast. There is moderate free fluid in pelvis and peritoneum. The colon is oedematous throughout with enhancing walls, but of normal calibre. The sigmoid colon is smooth and featureless. Small bowel, liver, spleen, kidneys, adrenals and pancreas are normal.\"><img  class=\"img-thumbnail mx-auto d-block\" style=\"max-height:150px;margin-bottom:10px;\" src=\"https:\/\/d32xxyeh8kfs8k.cloudfront.net\/images_Passmedicine\/xrb133.jpg\" alt=\"\" \/><\/a><\/div><\/div><\/div>","notes_hash":"d9d1ce2c481a73d49cfddd688e80c01b","knowledge_graph_node_id_link":1152,"links":"<table style='width:100%'><tr><td>NICE<\/td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"link_like_87\" data-linkid=\"87\" data-rating=\"1\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"\/><\/svg><\/button><span id=\"link_good_count_87\" class = \"link_good_count\" style=\"color:green; font-size:85%;\">20<\/span><button type=\"button\" style=\"\" id=\"link_dislike_87\" data-linkid=\"87\" data-rating=\"0\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"\/><\/svg><\/button><span id=\"link_bad_count_87\" class = \"link_bad_count\" style=\"color:red; font-size:85%;\">23<\/span><\/td><\/tr><tr><td colspan=\"2\"><a target=\"_blank\" href=\"https:\/\/www.nice.org.uk\/advice\/esmpb1\/chapter\/key-points-from-the-evidence\">Clostridium difficile infection: risk with broad-spectrum antibiotics<\/a><\/td><\/tr><\/table><br><br><table style='width:100%'><tr><td>Canadian Medical Journal<\/td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"link_like_854\" data-linkid=\"854\" data-rating=\"1\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"\/><\/svg><\/button><span id=\"link_good_count_854\" class = \"link_good_count\" style=\"color:green; font-size:85%;\">14<\/span><button type=\"button\" style=\"\" id=\"link_dislike_854\" data-linkid=\"854\" data-rating=\"0\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"\/><\/svg><\/button><span id=\"link_bad_count_854\" class = \"link_bad_count\" style=\"color:red; font-size:85%;\">13<\/span><\/td><\/tr><tr><td colspan=\"2\"><a target=\"_blank\" href=\"http:\/\/www.cmaj.ca\/content\/179\/8\/767\/F3.large.jpg\">Relative risk of developing Clostridium difficile<\/a><\/td><\/tr><\/table><br><br><table style='width:100%'><tr><td>Medcomic<\/td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"link_like_2062\" data-linkid=\"2062\" data-rating=\"1\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"\/><\/svg><\/button><span id=\"link_good_count_2062\" class = \"link_good_count\" style=\"color:green; font-size:85%;\">33<\/span><button type=\"button\" style=\"\" id=\"link_dislike_2062\" data-linkid=\"2062\" data-rating=\"0\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"\/><\/svg><\/button><span id=\"link_bad_count_2062\" class = \"link_bad_count\" style=\"color:red; font-size:85%;\">13<\/span><\/td><\/tr><tr><td colspan=\"2\"><a target=\"_blank\" href=\"https:\/\/www.medcomic.com\/medcomic\/clostridium-difficile-infection\">Clostridium difficile Infection<\/a><\/td><\/tr><\/table><br><br><table style='width:100%'><tr><td>NICE<\/td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"link_like_2048\" data-linkid=\"2048\" data-rating=\"1\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"\/><\/svg><\/button><span id=\"link_good_count_2048\" class = \"link_good_count\" style=\"color:green; font-size:85%;\">40<\/span><button type=\"button\" style=\"\" id=\"link_dislike_2048\" data-linkid=\"2048\" data-rating=\"0\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"\/><\/svg><\/button><span id=\"link_bad_count_2048\" class = \"link_bad_count\" style=\"color:red; font-size:85%;\">11<\/span><\/td><\/tr><tr><td colspan=\"2\"><a target=\"_blank\" href=\"https:\/\/www.nice.org.uk\/guidance\/ng199\/chapter\/Recommendations\">2021 Clostridioides difficile infection guidelines<\/a><\/td><\/tr><\/table>","media":"<table><tr><td colspan=\"2\"><a href=\"#\" class=\"media_link\" data-url=\"https:\/\/www.youtube.com\/embed\/Bpe94DaI6Pc\" data-description=\"Understanding Clostridium Difficile Infection\" data-upvotes=\"2\" data-downvotes=\"0\" data-media=\"1501\"><img border=\"0\" class=\"img-thumbnail\" alt=\"YouTube\" src=\"https:\/\/i1.ytimg.com\/vi\/Bpe94DaI6Pc\/mqdefault.jpg\" style=\"max-width:150px;\"><\/a><\/td><\/tr><tr ><td style=\"padding-top:10px\" colspan=\"2\"><a style=\"\" href=\"#\" class=\"media_link\" data-url=\"https:\/\/www.youtube.com\/embed\/Bpe94DaI6Pc\" data-description=\"Understanding Clostridium Difficile Infection\" data-upvotes=\"2\" data-downvotes=\"0\" data-media=\"1501\">Understanding Clostridium Difficile Infection<\/a><\/td><\/tr><tr><td><span ><small>Zero To Finals - YouTube<\/small><\/span><\/td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"media_like_2644\" data-mediaid=\"2644\" data-rating=\"1\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"\/><\/svg><\/button><span id=\"media_good_count_2644\" class = \"media_good_count\" style=\"color:green; font-size:85%;\">2<\/span><button type=\"button\" style=\"\" id=\"media_dislike_2644\" data-mediaid=\"2644\" data-rating=\"0\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"\/><\/svg><\/button><span id=\"media_bad_count_2644\" class = \"media_bad_count\" style=\"color:red; font-size:85%;\">0<\/span><\/td><\/tr><\/table>","concepts_for_notes":{"987":{"concept_text":"Clindamycin treatment is associated with a high risk of <i>C. difficile<\/i>","concept_percentile":"72"},"1489":{"concept_text":"In life-threatening <i>C. difficile<\/i> infection treatment is with ORAL vancomycin and IV metronidazole","concept_percentile":"95"},"1524":{"concept_text":"Oral vancomycin is the first line antibiotic for use in patients with <i>C. difficile<\/i> infection","concept_percentile":"51"},"1773":{"concept_text":"PPIs are a risk factor for <i>C. difficile<\/i> infection ","concept_percentile":"69"},"4516":{"concept_text":"If <i> C. difficile <\/i> does not respond to first-line vancomycin , oral fidaxomicin should be used next, except in life-threatening infections","concept_percentile":"57"},"11463":{"concept_text":"If a first episode of <i>C. difficile <\/i> doesn't respond to either vancomycin or fidaxomicin then oral vancomycin +\/- IV metronidazole should be tried","concept_percentile":"73"},"11464":{"concept_text":"A recurrent episode of <i>C. difficile<\/i> within 12 weeks of symptom resolution should be treated with oral fidaxomicin","concept_percentile":"67"}},"category_name":"Gastroenterology \/ Nutrition","subcategory_name":"Gastroenterology \/ Nutrition","comment_count":4},"",[]]